14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 84.019 Session: Virology and Viral Infections (Non-HIV) Date: Friday, March 12, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Inhibition of high risk HPV-31 in human cervical epithelial cells in vitro by the PC-PLC inhibitor LMV-601 E. Amtmann 1 , F. Mayer 2 , H. Pink 1 , W. Baader 1 1 German Cancer Research Centre (DKFZ), Heidelberg, Germany, 2 Lumavita AG, Basel, Switzerland Background: Expression of early genes and episomal DNA replication of human papilloma virus (HPV) is dependent from an active AP1 complex. Activation of AP1 was shown to be precluded by inhibition of phosphatidylcholine specific phospholipase C (PC-PLC). We studied the effect of the PC-PLC inhibitor LMV-601 on HPV-31 infected 9E cervical epithelial cells (CIN 612 9E). LMV-601 is (-)-exo/exo-O-Tricyclo-[5.2.1.0(2,6)]-dec-9-yl-dithiocarbonate potassium salt. Tricyclo- [5.2.1.0(2,6)]-dec-9-yl-dithiocarbonate potassium salt consists of 8 isomers (4 diastereomers, each having 2 enantiomers) and became known under the code D609, first synthesized in 1984 by Merz and Co in co-operation with the German Cancer Research Centre (DKFZ). The pure (-)- exo/exo isomer was first isolated in 2006 and is developed by Lumavita AG as an antiviral drug. Methods: 9E HPV-31 infected cervical epithelial cells were from L.A. Laimins, Chicago. (a) Short term study: After 72 h treatment, effect on cell growth, HPV-31 specific DNA (Southern Blotting) and RNA (Northern Blotting) was assessed. (b) Long term treatment (9 passages): After each passage, viral RNA and DNA levels, and cell morphology were assessed. Results: (a) Short term study: LMV-601 displayed a dose dependent inhibitory effect on cell growth(IC50 16 g/mL), HPV-31 specific RNA expression (IC50 10.69 g/mL) and DNA content (62.5 % reduction at the highest dose tested, i.e. 32 g/mL). (b) Long term treatment: The number of passages required to reduce the amount of HPV-31 specific RNA by 50% (T50RNA) was 2.23 at 3.3 g/mL LMV-601 and < 1 at 10 g/mL LMV-601. The corresponding T50DNA values were 3.28 and < 1, respectively. After six passages the growth rate of the cells was reduced and the morphology of the cells changed from the spindle form to a normal phenotype. After passage 9, cells were enlarged, became senescent (identified by expression of the senescence marker beta-gal), and ceased to grow. When human, non-HPV immortalized HaCat keratinocytes were treated with the same concentrations of LMV-601, neither cumulative inhibition of growth rate nor induction of senescence could be observed. Conclusion: LMV-601 inhibits HPV-31 specific RNA expression and DNA replication. Furthermore, these results support the hypothesis that chronic treatment with LMV-601 “cures” pre-cancerous 9E keratinocytes by elimination of HPV genomes.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 84.020 Session: Virology and Viral Infections (Non-HIV) Date: Friday, March 12, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation The pain topography caused by misdiagnosed zoster K. Duraku 1 , N. Como 2 , E. Meta 1 , D. Kraja 3 , A. Kica 1 1 HUC, Tirane, Albania, 2 University Hospital Centre "Mother Theresa", Tirana, AL, Albania, 3 Faculty of Medicine, Tirane, Albania Background: In Herpes Zoster, the pain precedes dermatome manifestation from 10–12 hours to 2–5 days even to 10 days. Zosterian pain last, however it's intermittent. Our goal in this study is in highlighting the topographic variety of Zosterian pain and initial misdiagnose related with it. In this study we have included 202 cases of Herpes Zoster. 97 of the them were initially not identified as Herpes Zoster. The group age was 19–78 years old, time period from 1998–2009. 37 of them were HIV positive. In our cases pain precedes exantematic manifestation from 18 to 68 hours. Methods: The cases were assessed based on correlation between neurotics zosterian pain and initial nosology. Results: According to pain location we distinguished these initial misdiagnoses: Location Diagnosis Number of cases Head migraine 8 sinusitis frontal 2 otitis 2 ophtalmitis 3 arthritis temporo – mandibular 1 odontalgya 2 Thorax angina pectoris 3 pericarditis 2 pleuritis 13 pneumonia 11 Abdomen abdominal colic 6 kidney colic 4 hepatic colic 4 cholecystitis 2 mezenterial thrombosis 1 orchitis 2 Upper extremites cervical racialgya 5 cervical spondylarthrose 7 thorax racialgya 6 scapulo-humeral bursitis 2 Lower extremites ischialgya 7 discal hernia 1 angiopathies 2 polymialgya rheumatica 1 coxo-femoral arthritis 2 Conclusion: 1) Zoster cases identified wrong initially were 48.02 %. 2) Incorrect nosologies conditioned by pain syndrome were 25. 3) Misdiagnoses depends on dermatome affected by zoster. 4) Neuritic pain that precedes zoster dermatomes needs to be considered in diagnosis of pathologies with pain syndrome.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236: When citing these abstracts please
Page 285: When citing these abstracts please
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

Create successful ePaper yourself

Delete template?

Save as template?